The HDAC inhibitor romidepsin renders liver cancer vulnerable to RTK targeting and immunologically activeCelia Sequera(Centre National de la Recherche Scientifique), Flavio Maina(Centre National de la Recherche Scientifique)Nature CommunicationsAugust 25, 202510.1038/s41467-025-62934-0Cited by 11SaveCiteExport RISWatch citationsRelated PapersEstablishment of a mouse hepatocellular carcinoma tumoroid panel recapitulating inter- and intra- heterogeneity for disease modelling and combinatorial drug discovery|Cell Communication and Signaling|2025|3